Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis
Advanced Science · 2025-05 · 12 (19)
DOI: 10.1002/advs.202405434 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, online erschienen am 22.03.2025. Verfasst von Shuo Liu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Columbia University, New York, NY, 10032, USA. Hauptthemen laut MEDLINE: MicroRNAs, Liposomes, Idiopathic Pulmonary Fibrosis, Pulmonary Fibrosis. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIH HHS, American Heart Association.
Abstract (Originalsprache)
Idiopathic pulmonary fibrosis (IPF) remains an incurable form of interstitial lung disease with sub‐optimal treatments that merely address adverse symptoms or slow fibrotic progression. Here, inhalable hsa‐miR‐30a‐3p‐loaded liposomes (miR‐30a) for the treatment of bleomycin‐induced pulmonary fibrosis in mice are presented. It was previously found that exosomes (Exo) derived from lung spheroid cells are therapeutic in multiple animal models of pulmonary fibrosis and are highly enriched for hsa‐miR‐30a‐3p. The present study investigates this miRNA as a singular factor to treat IPF. Liposomes containing miR‐30a mimic can be delivered to rodents through dry powder inhalation. Inhaled miR‐30a and Exo consistently lead to improved pulmonary function across six consecutive pulmonary function tests and promote de‐differentiation of profibrotic myofibroblasts. The heterogenous composure of Exo also promotes reparative alveolar type I and II cell remodeling and vascular wound healing through broad transforming growth factor‐beta signaling downregulation, while miR‐30a targets myofibroblast de‐differentiation through CNPY2/PERK/DDIT3 signaling. Overall, inhaled miR‐30a represses the epithelial‐mesenchymal transition of myofibroblasts, providing fibrotic attenuation and subsequent improvements in pulmonary function.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Columbia University, New York, NY, 10032, USA.
- Department of Molecular Biomedical Sciences, North Carolina State University, Raleigh, NC, 27606, USA.
- Comparative Medicine Institute, North Carolina State University, Raleigh, NC, 27606, USA.
- Department of Pulmonary, Allergy and Critical Care Medicine, Columbia University College of Physicians and Surgeons, New York, NY, 10032, USA.
- Xsome Biotech Inc., Raleigh, NC, 27606, USA.
- Joint Department of Biomedical Engineering, University of North Carolina at Chapel Hill and North Carolina State University, Raleigh/Chapel Hill, NC, 27606, USA.
ORCID-Profile: Ke Cheng
Förderung
- NHLBI NIH HHS
- NIH HHS
- American Heart Association
- NCATS NIH HHS
- National Institutes of Health
Zitieren
APA
Liu, S., Popowski, K. D., Eckhardt, C. M., Zhang, W., Li, J., Jing, Y., Silkstone, D., Belcher, E., Cislo, M., Hu, S., Lutz, H., Ghodsi, A., Liu, M., Dinh, P. C., & Cheng, K. (2025). Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis. Advanced Science, 12(19). https://doi.org/10.1002/advs.202405434
Vancouver
Liu S, Popowski KD, Eckhardt CM, Zhang W, Li J, Jing Y, et al. Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis. Advanced Science. 2025;12(19). doi:10.1002/advs.202405434
BibTeX
@article{Liu2025,
author = {Liu, Shuo and Popowski, Kristen D and Eckhardt, Christina M and Zhang, Weihang and Li, Junlang and Jing, Yujia and Silkstone, Dylan and Belcher, Elizabeth and Cislo, Megan and Hu, Shiqi and Lutz, Halle and Ghodsi, Asma and Liu, Mengrui and Dinh, Phuong-Uyen C and Cheng, Ke},
title = {Inhalable Hsa‐miR‐30a‐3p Liposomes Attenuate Pulmonary Fibrosis},
journal = {Advanced Science},
year = {2025},
volume = {12},
number = {19},
doi = {10.1002/advs.202405434}
}
EUVIMED